Vivendal Comp 160 mg/12,5 mg Filmdragerad tablett

Country: Sweden

Language: Swedish

Source: Läkemedelsverket (Medical Products Agency)

Buy It Now

Active ingredient:

hydroklortiazid; valsartan

Available from:

Sandoz A/S

ATC code:

C09DA03

INN (International Name):

hydrochlorothiazide; valsartan

Dosage:

160 mg/12,5 mg

Pharmaceutical form:

Filmdragerad tablett

Composition:

valsartan 160 mg Aktiv substans; hydroklortiazid 12,5 mg Aktiv substans

Class:

Apotek

Prescription type:

Receptbelagt

Therapeutic area:

Valsartan och diuretika

Product summary:

Förpacknings: Blister, 7 tabletter (plast/Al); Blister, 7 tabletter (Al); Blister, 10 tabletter (Al); Blister, 14 tabletter (Al); Blister, 15 tabletter (Al); Blister, 20 tabletter (Al); Blister, 28 tabletter (Al); Blister, 30 tabletter (Al); Blister, 50 tabletter (Al); Blister, 56 tabletter (Al); Blister, 60 tabletter (Al); Blister, 84 tabletter (Al); Blister, 90 tabletter (Al); Blister, 98 tabletter (Al); Blister, 100 tabletter (Al); Blister, 280 tabletter (Al); Blister, 10 tabletter (plast/Al); Blister, 14 tabletter (plast/Al); Blister, 15 tabletter (plast/Al); Blister, 20 tabletter (plast/Al); Blister, 28 tabletter (plast/Al); Blister, 30 tabletter (plast/Al); Blister, 50 tabletter (plast/Al); Blister, 56 tabletter (plast/Al); Blister, 60 tabletter (plast/Al); Blister, 84 tabletter (plast/Al); Blister, 90 tabletter (plast/Al); Blister, 98 tabletter (plast/Al); Blister, 100 tabletter (plast/Al); Blister, 280 tabletter (plast/Al); Blister, 50 x 1 tabletter, endos (Al); Blister, 50 x 1 tabletter, endos (plast/Al)

Authorization status:

Godkänd

Authorization date:

2011-04-15

Patient Information leaflet

                                PACKAGE LEAFLET: INFORMATION FOR THE USER
Vivendal Comp 80 mg /12.5 mg film-coated tablets
Vivendal Comp 160 mg /12.5 mg film-coated tablets
Vivendal Comp 160 mg /25 mg film-coated tablets
Vivendal Comp 320 mg /12.5 mg film-coated tablets
Vivendal Comp 320 mg /25 mg film-coated tablets
Valsartan/hydrochlorothiazide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Vivendal Comp is and what it is used for
2.
What you need to know before you take Vivendal Comp
3.
How to take Vivendal Comp
4.
Possible side effects
5.
How to store Vivendal Comp
6.
Contents of the pack and other information
1.
WHAT VIVENDAL COMP IS AND WHAT IT IS USED FOR
Vivendal Comp film-coated tablets contain two active substances called
valsartan and
hydrochlorothiazide. Both of these substances help to control high
blood pressure (hypertension).

VALSARTAN belongs to a class of medicines known as “angiotensin II
receptor antagonists”,
which help to control high blood pressure. Angiotensin II is a
substance in the body that
causes vessels to tighten, thus causing your blood pressure to
increase. Valsartan works by
blocking the effect of angiotensin II. As a result, blood vessels
relax and blood pressure is
lowered.

HYDROCHLOROTHIAZIDE belongs to a group of medicines called thiazide
diuretics (also
known as “water tablets”). Hydrochlorothiazide increases urine
output, which also lowers
blood pressure.
Vivendal Comp is used to treat high blood pressure which is not
adequately controlled by a single
substance a
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                MARKNADSFÖRS EJ FÖR NÄRVARANDE.
_Produktinformation_
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet English 18-03-2022
Public Assessment Report Public Assessment Report English 21-02-2013